
Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CAN-2409 for the treatment of patients with newly diagnosed localized, intermediate-to-high-risk prostate cancer, according to a press release from the developer, Candel …